Unexpected Synergy Reveals New Therapeutic Strategy in SCLC.


Massachusetts General Hospital Cancer Center, Boston, MA, USA; Harvard Medical School, Boston, MA, USA. Electronic address: [Email]


DNA damage repair (DDR) inhibition and immune checkpoint blockade (ICB) have each individually shown modest clinical activity in small cell lung cancer (SCLC). Recently, Sen and colleagues (Cancer Discov. 2019;https://doi.org/10.1158/2159-8290.CD-18-1020) demonstrated that DDR inhibition can activate the stimulator of interferon genes (STING) innate immune pathway, providing strong rationale for combining DDR inhibition and ICB to treat SCLC.


PARP inhibitor,PD-1,PD-L1,SCLC,checkpoint kinase 1 inhibitor,immune checkpoint blockade,